BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DTU.dk//NONSGML DTU.dk//EN
CALSCALE:GREGORIAN
BEGIN:VEVENT
DTSTART:20170706T130000
DTEND:20170706T160000
SUMMARY:PhD Defense by Sabrina Lyngbye Wendt: Modeling Pharmacokinetics and Pharmacodynamics of Glucagon for Simulation of the Glucoregulatory System in Patients with Type 1 Diabetes
DESCRIPTION:<p>PhD Defense by <a href="http://orbit.dtu.dk/en/persons/sabrina-lyngbye-wendt(053fcca6-8b59-439b-ad9a-4abe1507ae4f).html" target="_blank">Sabrina Lyngbye Wendt</a>, Thursday, July 6, 13.00 &ndash; 16.00. The Technical University of Denmark\nBuilding 101, Meeting room 1.</p>\n<p><strong>Abstract:\n</strong><br>\nThe goal of this thesis was to develop a pharmacokinetics/pharmacodynamics (PK/PD) model for glucagon. The proposed PD model included multiplication of the stimulating glucagon effect and inhibiting insulin effect on the endogenous glucose production (EGP). Moreover, the concentration-response relationship of glucagon and EGP was characterized by a non-linear function, where the response saturated for high concentrations of glucagon. The novel EGP model extended Hovorka's glucoregulatory model to include the effect of glucagon. The PK/PD model described both regular glucagon and a novel glucagon analogue in healthy dogs. The extended glucoregulatory model translated to the human species and described glucose-insulin-glucagon dynamics in healthy subjects and patients with type 1 diabetes (T1D). The extended glucoregulatory model was successfully validated by leave-one-out cross-validation in seven T1D patients which justified its use for simulations. The final model parameters were estimated from three to four datasets from each patient. The validated extended glucoregulatory model was used for in silico studies. The model replicated a clinical study of the effect of glucagon at varying insulin levels. The simulations also suggested new glucagon doses to be tested in a similar in vivo study to provide new insight to the relationship between insulin, glucagon, and EGP. Finally, the model was used to conduct a large original simulation study investigating an insulin&nbsp;dependent glucagon dosing regimen for treatment of insulin-induced mild hypoglycemia.</p>\n<p><strong>Principal supervisor:</strong>\nAssociate Professor John Bagterp J&oslash;rgensen, DTU Compute.\n<br>\n<strong>Co-supervisors</strong>: Professor Henrik Madsen, DTU Compute, and Dr. Carsten Boye Knudsen, Zealand Pharma A/S.\n</p>\n<p><strong>Evaluation Commitee:\n</strong><br>\nAssociate Professor Uffe H&oslash;gsbro Thygesen, DTU Compute.\n<br>\nDirector of Research Roman Hovorka, University of Cambridge, Great Britain.<br>\nAssociate Professor Chiara Dalla-Man, University of Padova, Italy.</p>\n<p><strong>Chairperson</strong>: Associate Professor Yiqiu Dong, DTU Compute.</p>\n<p>All are welcome</p>
X-ALT-DESC;FMTTYPE=text/html:<p>PhD Defense by <a href="http://orbit.dtu.dk/en/persons/sabrina-lyngbye-wendt(053fcca6-8b59-439b-ad9a-4abe1507ae4f).html" target="_blank">Sabrina Lyngbye Wendt</a>, Thursday, July 6, 13.00 &ndash; 16.00. The Technical University of Denmark\nBuilding 101, Meeting room 1.</p>\n<p><strong>Abstract:\n</strong><br>\nThe goal of this thesis was to develop a pharmacokinetics/pharmacodynamics (PK/PD) model for glucagon. The proposed PD model included multiplication of the stimulating glucagon effect and inhibiting insulin effect on the endogenous glucose production (EGP). Moreover, the concentration-response relationship of glucagon and EGP was characterized by a non-linear function, where the response saturated for high concentrations of glucagon. The novel EGP model extended Hovorka's glucoregulatory model to include the effect of glucagon. The PK/PD model described both regular glucagon and a novel glucagon analogue in healthy dogs. The extended glucoregulatory model translated to the human species and described glucose-insulin-glucagon dynamics in healthy subjects and patients with type 1 diabetes (T1D). The extended glucoregulatory model was successfully validated by leave-one-out cross-validation in seven T1D patients which justified its use for simulations. The final model parameters were estimated from three to four datasets from each patient. The validated extended glucoregulatory model was used for in silico studies. The model replicated a clinical study of the effect of glucagon at varying insulin levels. The simulations also suggested new glucagon doses to be tested in a similar in vivo study to provide new insight to the relationship between insulin, glucagon, and EGP. Finally, the model was used to conduct a large original simulation study investigating an insulin&nbsp;dependent glucagon dosing regimen for treatment of insulin-induced mild hypoglycemia.</p>\n<p><strong>Principal supervisor:</strong>\nAssociate Professor John Bagterp J&oslash;rgensen, DTU Compute.\n<br>\n<strong>Co-supervisors</strong>: Professor Henrik Madsen, DTU Compute, and Dr. Carsten Boye Knudsen, Zealand Pharma A/S.\n</p>\n<p><strong>Evaluation Commitee:\n</strong><br>\nAssociate Professor Uffe H&oslash;gsbro Thygesen, DTU Compute.\n<br>\nDirector of Research Roman Hovorka, University of Cambridge, Great Britain.<br>\nAssociate Professor Chiara Dalla-Man, University of Padova, Italy.</p>\n<p><strong>Chairperson</strong>: Associate Professor Yiqiu Dong, DTU Compute.</p>\n<p>All are welcome</p>

URL:https://www.dtu.dk/sitecore/content/institutter/compute/dtu_compute_old/forside/kalender/2017/07/phd-defense-by-sabrina-lyngbye-wendt
DTSTAMP:20260517T091500Z
UID:{CA43D05F-70EC-4A2D-91BA-E9D190171A1B}-20170706T130000-20170706T130000
LOCATION: The Technical University of Denmark, Building 101, Meeting room 1
END:VEVENT
END:VCALENDAR